Targeted protein degradation (TPD) mediates protein level through small molecule induced
redirection of E3 ligases to ubiquitinate neo-substrates and mark them for proteasomal …

Molecular glue (MG) degraders are monovalent small molecule compounds that co-opt E3
ubiquitin ligases to target neo-substrates for proteasomal degradation. Here, we provide a …

Activating apoptosis has long been viewed as an anti-cancer process, but recently
increasing evidence has accumulated that induction of ferroptosis has emerged as a …

Protein homeostasis is tightly regulated, with damaged or misfolded proteins quickly
eliminated by the proteasome and autophagosome pathways. By co-opting these …

Targeted protein degradation with monovalent molecular glue degraders is a powerful
therapeutic modality for eliminating disease causing proteins. However, rational design of …

Alkenyl oxindoles have been characterized as autophagosome-tethering compounds
(ATTECs), which can target mutant huntingtin protein (mHTT) for lysosomal degradation. In …

Targeted protein degradation (TPD) using the ubiquitin proteasome system (UPS) is a
rapidly growing drug discovery modality to eliminate pathogenic proteins. Strategies for TPD …

Alkenyl oxindoles have been characterized as autophagosome-tethering compounds
(ATTECs), which can target mutant huntingtin protein (mHTT) for lysosomal degradation. In …

Targeted protein degradation is mediated by small molecules that induce or stabilize protein–
protein interactions between targets and the ubiquitin–proteasome machinery. Currently …

Proteolysis targeting chimeras (PROTACs) offer a promising degradation-based alternative
to classical inhibition-based therapeutic interventions. PROTACs are hetero-bifunctional …